Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Calidi Biotherapeutics, Inc. (CLDI) had Stock-Based Compensation of $1.13M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
$-5.71M |
|
-- |
|
-- |
|
$5.66M |
|
$-5.66M |
|
$-0.09M |
|
$-5.76M |
|
$-5.76M |
|
$-5.76M |
|
$-5.76M |
|
$-5.76M |
|
$-5.76M |
|
$-5.66M |
|
$-5.26M |
|
2.88M |
|
2.88M |
|
$-1.99 |
|
$-1.99 |
|
| Balance Sheet Financials | |
$6.05M |
|
$0.93M |
|
$3.30M |
|
$9.35M |
|
$5.35M |
|
$0.83M |
|
$1.92M |
|
$7.28M |
|
$2.08M |
|
$2.08M |
|
$2.08M |
|
2.88M |
|
| Cash Flow Statement Financials | |
$-12.01M |
|
$-0.06M |
|
$7.64M |
|
$9.81M |
|
$5.38M |
|
$-4.43M |
|
|
Stock-Based Compensation |
$1.13M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.13 |
|
-- |
|
-- |
|
0.28 |
|
0.83 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-12.07M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-277.51% |
|
-277.50% |
|
-61.61% |
|
-198.52% |
|
$0.72 |
|
$-4.20 |
|
$-4.17 |
|